Company Overview - TG Therapeutics is a commercial-stage biopharmaceutical company focused on developing innovative therapies for hematologic cancers and autoimmune disorders, utilizing monoclonal antibodies and targeted therapies to meet unmet medical needs in oncology and immunology [5][7] - The company reported a market capitalization of $4.6 billion and a revenue of $616.3 million for the trailing twelve months (TTM), with a net income of $447.2 million [4] Recent Developments - On February 17, 2026, ACT Capital Management disclosed a new position in TG Therapeutics, acquiring 268,875 shares valued at $8,015,164, which represents 6.5% of ACT's $123.67 million in reportable U.S. equity assets as of December 31, 2025 [1][2][6] - The acquisition reflects a strategic move by ACT Capital Management, indicating confidence in TG Therapeutics' potential for growth [9] Product Performance - TG Therapeutics' multiple sclerosis treatment, BRIUMVI, has become a core product, with sales reaching approximately $606.9 million in 2025, nearly doubling from the previous year, contributing significantly to the total annual revenue of about $616.3 million [8] - The drug generated $182.7 million in U.S. revenue in the fourth quarter of 2025, showcasing strong momentum in adoption among neurologists [8] Future Outlook - The company is targeting total global revenue of approximately $875 million to $900 million for 2026, primarily driven by continued adoption of BRIUMVI and expanding international commercialization efforts [9] - If TG Therapeutics exceeds these projections, it could signal a turnaround for the company, which may be a key factor in ACT Capital Management's investment decision [9]

Core Insights - TG Therapeutics Inc. (NASDAQ:TGTX) is recognized as one of the 10 most shorted biotech stocks to buy according to hedge funds [1] - The company reported Q4 revenue of $192.6 million, slightly below consensus estimates of $193.3 million [1] - CEO Michael Weiss highlighted 2025 as a promising year for TG Therapeutics, particularly due to the momentum surrounding BRIUMVI [1] Financial Performance - The company experienced significant year-over-year growth both in the U.S. and globally, attributed to increased adoption and availability of its products [2] - TG Therapeutics is advancing its late-stage clinical programs and strengthening its financial foundation as it approaches 2026 [2] - The company is focused on delivering value to patients, healthcare providers, and shareholders through disciplined business operations and good financial guidance [2] Product Development - BRIUMVI is a key product for TG Therapeutics, aimed at transforming the treatment landscape for B-cell mediated diseases, including multiple sclerosis [5][6] - The company specializes in acquiring, developing, and commercializing innovative therapies to improve patient outcomes and quality of life [5][6] Analyst Insights - JPMorgan analyst Brian Cheng reduced the price target for TG Therapeutics from $49 to $46 while maintaining an Overweight rating, indicating an upside potential of over 57% [4]

Market Overview - Equity markets are experiencing volatility due to geopolitical uncertainties and elevated interest rates, which are unfavorable for investors accustomed to ultra-low rates [1] - Companies that can fund their own growth through profits rather than relying on external financing are becoming increasingly important in the current economic environment [1] Investment Strategy - BlackRock has recommended focusing on high-quality income and durable growth opportunities, suggesting that the current market presents a unique chance since the Global Financial Crisis [2] - Durable growth in a high-interest environment is associated with companies that exhibit healthy profitability, leading to a search for profitable growth stocks that do not require high-interest financing [3] Methodology for Stock Selection - A list of 13 profitable growth stocks was compiled, focusing on companies with a market cap of at least $2 billion and expected revenue growth of at least 30% over the next year [5] - The stocks were sorted by net profit and are also favored by hedge funds, indicating strong market interest [5][6] Company Highlights ARMOUR Residential REIT, Inc. (NYSE:ARR) - Reported Q4 fiscal 2025 net income of $208.7 million, or $1.86 per share, with net interest income of $50.4 million [7] - Raised $3.8 million through preferred stock and $138 million through common stock, issuing approximately 7.5 million common shares [8] - Distributed dividends of $0.24 per common share monthly, totaling $0.72 for the quarter, with management expressing confidence in the company's strategy and dividend outlook for 2026 [9][10] TG Therapeutics, Inc. (NASDAQ:TGTX) - Reported Q4 net income of $23 million, contributing to a full-year net income of $447.2 million, with total global revenue of $616 million for 2025 [13] - Operating expenses for the year were approximately $328 million, projected to rise to $350 million in 2026, plus an additional $100 million for manufacturing and start-up activities [14] - The company expects U.S. revenue to grow sequentially in Q1 to approximately $185 million to $190 million [14] Gildan Activewear Inc. (NYSE:GIL) - Reported Q4 revenue of $1.08 billion, a 31.4% year-over-year increase, and Non-GAAP EPS of $0.96, slightly above estimates [17] - Operating cash flows increased by 59.8%, and free cash flows rose by 46.4% year-over-year [17] - Returned $33 million to shareholders through dividends and share repurchases, with a 10% dividend increase announced for 2026 [18]

Core Insights - TG Therapeutics, Inc. (NASDAQ:TGTX) is identified as a promising investment opportunity in the biotech sector, particularly due to its financial performance and product growth [1][2]. Financial Performance - For fiscal Q4 2025, TG Therapeutics reported total revenue of $192.6 million, with full-year revenue reaching $616.3 million [1]. - The U.S. net product revenue for BRIUMVI was $182.7 million in Q4 2025, marking a quarterly growth of approximately 20% year-over-year, and $594.1 million for the full year, reflecting a year-over-year increase of about 92% [1]. Product Expansion - The company has expanded the commercialization of BRIUMVI outside the United States through its partnership with Neuraxpharm, with approvals in regions such as the European Union, United Kingdom, Switzerland, Australia, Kuwait, and the United Arab Emirates [2]. - For the full year 2026, TG Therapeutics aims for total global revenue between $875 million and $900 million, with U.S. net product revenue for BRIUMVI projected at approximately $825 million to $850 million [2]. Product Portfolio - TG Therapeutics is focused on the acquisition, development, and commercialization of innovative treatments for B-cell malignancies and autoimmune diseases, with a product portfolio that includes TG-1501, TG-1701, Ublituximab, and Umbralisib [3].

Group 1 - The article discusses TG Therapeutics (TGTX) and its potential growth in the multiple sclerosis (MS) market with the product Azer-Cel [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies [2] - Biotech Analysis Central offers a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not provide any specific financial data or performance metrics related to TG Therapeutics or its products [1][3][4]

Core Insights - The company is experiencing significant growth in the BRIUMVI product line, with a total global revenue of approximately $616 million in 2025, primarily driven by U.S. net sales of $594 million, reflecting a 92% year-over-year growth [4][8][19] - The company is advancing its subcutaneous (subcu) BRIUMVI program, targeting a potential launch in 2028, which could simplify treatment for patients and expand the market opportunity [2][12][13] - Confidence in BRIUMVI is bolstered by clinical data showing nearly 90% of patients were free from confirmed disability progression after six years of treatment, with a low relapse rate [3][10] Financial Performance - The company reported a net income of $447.2 million for 2025, translating to $2.77 per diluted share, compared to $23.4 million or $0.15 per diluted share in 2024 [20] - Operating income for the year was $123 million, with total operating expenses of approximately $328 million, aligning with prior guidance [19][22] - The company has completed a $100 million share repurchase program and authorized an additional $100 million, reflecting confidence in its long-term outlook [5][21] Market Position and Strategy - BRIUMVI is gaining market share in the competitive IV anti-CD20 segment, with strong demand and increasing physician confidence [10][13] - The company is expanding its field organization to enhance coverage in high-opportunity areas and increase prescriber engagement [11][12] - The partnership with Christina Applegate for the Next In MS initiative aims to provide resources and support for individuals living with multiple sclerosis, enhancing the company's community engagement [12][51] Future Outlook - The company expects to generate U.S. BRIUMVI net revenue of $825 million to $850 million in 2026, with total global revenue projected at $875 million to $900 million [12][15] - Upcoming catalysts include pivotal data from the subcutaneous BRIUMVI program and updates from the ENHANCE trial, which aims to consolidate dosing schedules [52][53] - The company anticipates continued growth driven by expanding prescriber adoption and a growing patient base with strong persistence on therapy [13][15]

Financial Data and Key Metrics Changes - TG Therapeutics reported approximately $616 million in total global revenue for 2025, with $594 million coming from U.S. net sales of BRIUMVI, marking a 92% year-over-year growth and a 20% sequential growth from Q4 over Q3 [5][20] - The company achieved a net income of $447.2 million for the full year 2025, or $2.77 per diluted share, compared to $23.4 million, or $0.15 per diluted share in 2024 [23][24] Business Line Data and Key Metrics Changes - BRIUMVI U.S. net revenue reached $594 million for the full year, with Q4 net sales of $183 million, reflecting sustained momentum and growth driven by new patient starts and prescriber expansion [12][20] - Breyanzi continues to strengthen its position in the anti-CD20 market, with a balanced mix of treatment-naive and switch patients contributing to its growth [13][14] Market Data and Key Metrics Changes - The company expects U.S. Breyanzi net revenue guidance for 2026 to be between $825 million and $850 million, with total global revenue projected at $875 million to $900 million [16] - The first quarter of 2026 is expected to see U.S. revenue grow sequentially to approximately $185 million to $190 million, despite typical seasonal headwinds [17] Company Strategy and Development Direction - TG Therapeutics aims to maximize the multi-billion dollar BRIUMVI opportunity while expanding its pipeline judiciously for sustained future growth [9] - The company is developing a self-administered subcutaneous BRIUMVI, targeting pivotal top-line data later this year or early next year, with a potential 2028 launch [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for BRIUMVI, citing strong patient persistence and physician confidence as key drivers [30][36] - The company anticipates generating positive cash flow in 2026 and beyond, providing financial flexibility within the biotech sector [9][24] Other Important Information - TG Therapeutics completed a $100 million share repurchase program and authorized an additional $100 million, reflecting confidence in the company's long-term outlook [10][24] - The partnership with Christina Applegate for the Next in MS initiative aims to provide resources and support for individuals living with MS, enhancing the company's presence in the community [11][15] Q&A Session Summary Question: Dynamics of sub-Q uptake in community practices - Management noted that they continue to gain shares in the IV segment, driven by clinical data and operational advantages, with no decrease in switches from Ocrevus to BRIUMVI [27][28] Question: Gross to net assumptions - Management indicated that gross to net can fluctuate, particularly in Q1 due to deductible resets, but this does not represent a structural change in their framework [31] Question: Proportion of new versus switch patients - Management confirmed record new patient enrollments and strong persistence, with repeat patients becoming a larger part of the business [34][36] Question: Incremental investments for sub-Q launch - Management stated that the overlap between the current field force for IV and sub-Q is about 80%, indicating minimal incremental costs for the sub-Q launch [46] Question: Market perspective on ENHANCE trial - Management believes that eliminating the second dose will enhance market share gains, as convenience is highly valued by both patients and centers [70][71]

Financial Data and Key Metrics Changes - TG Therapeutics reported approximately $616 million in total global revenue for 2025, with $594 million coming from U.S. net sales of BRIUMVI, marking a 92% year-over-year growth and a 20% sequential growth from Q4 over Q3 [5][20] - The company achieved a net income of $447.2 million for the full year 2025, or $2.77 per diluted share, compared to $23.4 million, or $0.15 per diluted share in 2024 [23][24] Business Line Data and Key Metrics Changes - BRIUMVI U.S. net sales for Q4 2025 were $183 million, contributing to a full-year total of $594 million, driven by new patient starts and increased prescriber engagement [12][20] - The gross margin for Q4 was slightly below typical due to timing of sales and a one-time inventory reserve [21] Market Data and Key Metrics Changes - The company continues to gain share in the IV anti-CD20 market, with strong growth across both academic and community settings [13][16] - The first quarter of 2026 is expected to see U.S. revenue grow sequentially to approximately $185 million-$190 million, despite typical seasonal headwinds [17] Company Strategy and Development Direction - TG Therapeutics aims to maximize the multi-billion dollar BRIUMVI opportunity while expanding its pipeline judiciously for sustained future growth [9] - The company is developing a self-administered subcutaneous BRIUMVI, targeting a potential 2028 launch, which could significantly expand its total addressable market [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of BRIUMVI, citing strong demand trends and physician confidence [16][18] - The company anticipates generating positive cash flow in 2026 and beyond, providing financial flexibility within the biotech sector [9][24] Other Important Information - TG Therapeutics completed a $100 million share repurchase program and authorized an additional $100 million, reflecting confidence in its long-term outlook [10][24] - The company is actively engaging in community support initiatives, such as the partnership with Christina Applegate for the Next in MS platform [11] Q&A Session Summary Question: Dynamics of sub-Q uptake in community practices - Management noted that they continue to gain shares in the IV segment, driven by clinical data and operational advantages, with no decrease in switches from Ocrevus to BRIUMVI [28][29] Question: Gross to net assumptions - Management indicated that gross to net can fluctuate, particularly in Q1 due to deductible resets, but this does not represent a structural change [31] Question: Proportion of new versus switch patients - Management confirmed record new patient enrollments and strong persistence, with repeat patients becoming a larger part of the business [36][37] Question: Incremental investments for sub-Q launch - Management stated that the overlap between the current field force for IV and sub-Q is about 80%, indicating minimal incremental costs for the sub-Q launch [46] Question: Market perspective on ENHANCE trial - Management believes that eliminating the second dose will enhance market share gains, as convenience is highly valued by patients and healthcare providers [71] Question: Early metrics from DTC campaign - Engagement metrics from the Next in MS initiative have exceeded expectations, indicating strong interest and interaction from patients and advocacy groups [75]

Financial Data and Key Metrics Changes - TG Therapeutics reported approximately $616 million in total global revenue for 2025, with $594 million coming from U.S. net sales of BRIUMVI, marking a 92% year-over-year growth and a 20% sequential growth from Q4 over Q3 [5][20] - The company achieved an operating income of $123 million for the year, with a net income of $447.2 million, or $2.77 per diluted share, compared to $23.4 million, or $0.15 per diluted share in 2024 [22][25] Business Line Data and Key Metrics Changes - BRIUMVI U.S. net revenue reached $594 million for the full year, with Q4 net sales of $183 million, reflecting sustained momentum and growth driven by new patient starts and prescriber expansion [12][20] - Breyanzi continues to strengthen its position in the anti-CD20 market, with a balanced mix of treatment-naive and switch patients contributing to its growth [13] Market Data and Key Metrics Changes - The company expects full-year U.S. Breyanzi net revenue guidance of $825 million-$850 million for 2026, with total global revenue projected at $875 million-$900 million [16] - The first quarter of 2026 is expected to see U.S. revenue grow sequentially to approximately $185 million-$190 million, despite typical seasonal headwinds [17] Company Strategy and Development Direction - TG Therapeutics aims to maximize the multi-billion dollar BRIUMVI opportunity while expanding its pipeline judiciously for sustained future growth [9] - The company is developing a self-administered subcutaneous BRIUMVI, targeting pivotal top-line data later this year or early next year, with a potential 2028 launch [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in generating positive cash flow in 2026 and beyond, highlighting the company's financial flexibility within the biotech sector [9] - The management team emphasized the importance of building a strong presence in the MS community and supporting patients beyond just commercializing BRIUMVI [11] Other Important Information - The company completed its first $100 million share repurchase program and authorized an additional $100 million, indicating confidence in its long-term outlook [23] - The partnership with Christina Applegate for the Next in MS initiative aims to provide resources and support for individuals living with MS [10] Q&A Session Summary Question: Dynamics of sub-Q uptake in community practices - Management noted that they continue to gain share in the IV segment and are not seeing decreases in switches from Ocrevus to BRIUMVI, with strong momentum across both private practice and academic centers [27][29] Question: Proportion of new versus switch patients - Management confirmed record new patient enrollments and strong persistence among existing patients, contributing to continued growth [35][38] Question: Incremental investments for sub-Q launch - Management indicated that the overlap between the current field force for IV and sub-Q is about 80%, suggesting minimal incremental costs for the sub-Q launch [42][47] Question: Market perspective on ENHANCE trial - Management believes that eliminating the second dose will enhance convenience for patients and could lead to market share gains [70][71] Question: Early metrics from DTC launch and Next in MS program - Engagement metrics from the Next in MS initiative have exceeded expectations, with positive feedback from customers and advocacy groups [75]

Core Insights - The company delivered $616 million in total global revenue for 2025, with $594 million in U.S. BRIUMVI net sales, reflecting a 92% year-over-year growth [1] - Performance was marked by consistent increases in new patient starts and a broadening prescriber base across both academic and community settings [1] - Management attributes sustained momentum to physician confidence in long-term data, particularly 6-year extension results showing 90% of patients remained disability-progression free [1] - The company achieved a rare biotech milestone of generating $123 million in operating income, providing financial flexibility for pipeline investment and share repurchases [1] - Strategic positioning emphasizes the '1-hour twice-yearly' maintenance profile, which management believes offers superior operational efficiency for infusion centers compared to competitors [1] - The 'Next In MS' partnership with Christina Applegate aims to build long-term category leadership by engaging patients beyond the clinical prescription [1]